• 08.30 - Brain metastases preclinical models, P. Steeg, USA
• 09.00 - Genomic Characterization of Brain Metastases Reveals Branched, Evolution and Metastasis-Specific Mutations, P. Brastianos, USA
• 09.30 - Brain metastases and methylation profile, C. Geisenberger, DE
• 10.00 - Circulating tumor cells and brain metastases outcome in HER2-positive breast cancer patients, J-Y. Pierga, FR

• 11.00 - Graded prognostic Indices at the age of molecular profiling and targeted therapies, M. Ahluwalia, USA
• 11.30 - Targeted therapies in BRAF-mutant brain metastatic melanoma patients, C. Mateus, FR

• 12.00 - Systemic therapy for breast cancer in the brain: future potential, D. Cameron, UK
• 12.30 - Targeted therapies and brain metastases in lung cancer patients, B. Besse, FR

• 13.30 - Immuno-Oncology in Brain Metastases Concept of Immuno-Oncology and Immunotherapy on Brain Metastases in lung cancer, F. Barlési - FR
• 14.00 - Immunotherapy on Brain Metastases un melanoma, S. Monestier-Gasmi - FR

• 14.30 - Innovative trial concepts in Brain Metastases, M. Mehta - USA
• 15.00 - Window of Opportunity studies in Brain Metastases, J-C. Tönn - DE

• 15.30 - Neuroimaging assessment of brain metastases in the targeted therapy era, A. Radbruch, DE

• 16.00 - Chemotherapy related cognitive deficits, S. Schagen, NL
• 16.30 - Neurocognitive assessment in BM, M. Klein, NL

Automatic Brain Metastases Planning: Fast Treatment. Focused Dose. Revolutionary Technology.
The biological response of brain metastases to stereotactic radiotherapy, R. Zakaria - UK